entertainment -WSS

entertainment

author：leisure time 2025-08-25 07:28:46 - browse：647

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

hotspot

focus

WSS

Diversifying clinical trials isn't enough to close racial gaps: study

Why Sanofi got shellacked over its spinoff

Meta's Zuckerberg and Chan on track to put $50 billion into science

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Eli Lilly to pay $200M for Beam’s stake in gene

Cassava reveals details — and problems — with Alzheimer's study

leisure time

entertainment

explore

Sports medicine is finally prioritizing gender equality

CDC recommends rationing of RSV shot due to shortages

In Memoriam: Notable people who died in 2023

Senate panel to vote on hospitals, PBMs, prisoner care

How one medical school became remarkably diverse

Testing for cancer recurrence creates a new limbo for patients

The high cost of giving birth even with insurance

Software glitch causes Tandem insulin pump to shutdown, FDA warns

DIEP, the 'gold standard' of breast reconstruction, is under threat

How to improve immunocompromised access to mAb treatments

explore

Biden's order seeks to regulate AI risk without stifling innovation

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Brain worms: The science behind RFK Jr.'s parasitic infection

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Chimpanzees, like humans and whales, get menopause: Study

Biden's order seeks to regulate AI risk without stifling innovation

hotspot

focus

leisure time

hotspot